Payment overview · 2025
General Payments
$91.27
4 reported records · 3 companies
Healthcare provider profile · identity verified
Eran Matalon, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SANTA ROSA, CA · NPI 1073656815
Verified facts
What the public records show
CMS Open Payments records show Eran Matalon, M.D. received $91.27 in general payments during 2025 across 4 reported records.
ABBVIE INC. accounted for 37.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Vraylar by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.93 | 37.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.77 | 31.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.57 | 31.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $91.27 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.93 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.93 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $28.77 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $28.77 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $28.77 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
209 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 691 | 166 |
| Levothyroxine Sodium | Levothyroxine Sodium | 502 | 102 |
| Gabapentin | Gabapentin | 317 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 265 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 222 | 65 |
| Furosemide | Furosemide | 210 | 43 |
| Eliquis | Apixaban | 209 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 204 | 59 |
| Losartan Potassium | Losartan Potassium | 196 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 193 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 180 | 46 |
| Omeprazole | Omeprazole | 178 | 52 |
| Metformin Hcl | Metformin Hcl | 175 | 48 |
| Trazodone Hcl | Trazodone Hcl | 167 | 45 |
| Simvastatin | Simvastatin | 143 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 37 |
| Potassium Chloride | Potassium Chloride | 136 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 53 |
| Lorazepam | Lorazepam | 114 | 22 |
| Mirtazapine | Mirtazapine | 105 | 33 |
| Allopurinol | Allopurinol | 101 | 25 |
| Sertraline Hcl | Sertraline Hcl | 97 | 25 |
| Carvedilol | Carvedilol | 96 | 22 |
| Levetiracetam | Levetiracetam | 93 | 14 |
| Xarelto | Rivaroxaban | 92 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 88 | 22 |
| Lisinopril | Lisinopril | 88 | 27 |
| Montelukast Sodium | Montelukast Sodium | 85 | 11 |
| Alprazolam | Alprazolam | 83 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 81 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 27 |
| Lamotrigine | Lamotrigine | 71 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 69 | 22 |
| Jardiance | Empagliflozin | 68 | 13 |
| Bupropion Xl | Bupropion Hcl | 65 | 12 |
| Clonazepam | Clonazepam | 60 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 60 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 13 |
| Finasteride | Finasteride | 57 | 14 |
| Acyclovir | Acyclovir | 55 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Estradiol | Estradiol | 50 | 12 |
| Lactulose | Lactulose | 50 | suppressed |
| Latanoprost | Latanoprost | 47 | suppressed |
| Lovastatin | Lovastatin | 47 | 14 |
| Metformin Hcl Er | Metformin Hcl | 46 | 12 |
| Olanzapine | Olanzapine | 45 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 41 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 40 | suppressed |
| Pregabalin | Pregabalin | 40 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 40 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 13 |
| Famotidine | Famotidine | 39 | 17 |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Celecoxib | Celecoxib | 38 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | 12 |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Topiramate | Topiramate | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 25 |
| Ozempic | Semaglutide | 36 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | 11 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | 11 |
| Atenolol | Atenolol | 32 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 19 |
| Xifaxan | Rifaximin | 32 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 31 | 11 |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 30 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 16 |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Vraylar | Cariprazine Hcl | 26 | suppressed |
| Phenobarbital | Phenobarbital | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 15 |
| Meloxicam | Meloxicam | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 15 |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Klor-Con 10 | Potassium Chloride | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Haloperidol | Haloperidol | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 12 |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 16 | suppressed |
| Risperidone Er | Risperidone Microspheres | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 13 |
| Bumetanide | Bumetanide | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $91.27 · 4 records | ABBVIE INC. | ABRYSVO, COMIRNATY, PREVNAR 20, QULIPTA, TRELEGY ELLIPTA, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error